Cancer Harboring BRAF Alterations

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Cancer Harboring BRAF Alterations trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT05503797

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, o…

United States254 participantsStarted 2023-02-21

Treatment: Plixorafenib

All recent trials (3 shown)

Active — Not RecruitingPhase 2

NCT02304809

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no…

France216 participantsStarted 2014-10-13

Treatment: Vemurafenib

TerminatedPhase 2

NCT04488003

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer trea…

United States104 participantsStarted 2021-01-07

Treatment: Ulixertinib, Physician's Choice